Fate Therapeutics FATE
NASDAQ FATE
$2.48 +0.06 (+2.48%)
As of: Sep 4, 2026 · 3:59 PM EDT

Fate Therapeutics (FATE) Price to Earnings (2013 - 2026)

Analysis

Fate Therapeutics (FATE) Price to Earnings (2013 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Fate Therapeutics 299.79 Mn 299.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10.65
Mar 31, 2026 -4.48
Dec 31, 2025 -3.48
Sep 30, 2025 -4.52
Jun 30, 2025 -3.77
Mar 31, 2025 -2.39
Dec 31, 2024 -3.25
Sep 30, 2024 -8.31
Jun 30, 2024 -9.28
Mar 31, 2024 -17.80
Dec 31, 2023 -8.45
Sep 30, 2023 -4.49
Jun 30, 2023 -8.06
Mar 31, 2023 -22.48
Dec 31, 2022 -15.95
Sep 30, 2022 -25.72
Jun 30, 2022 -29.15
Mar 31, 2022 -50.54
Dec 31, 2021 -81.07
Sep 30, 2021 -104.02